Humanigen Inc (fka HGENQ)

[cowtown jay]

Chapter 2 The ancillary benefits

In our first quarter 10-Q, the company described current trials of lenzilumab that were all sponsored by partners. The trials focused on CMML, aGvHD, and CAR-T.

In each indication, lenzilumab promises to have demonstrated game-changing improvement, which could lead to long-delayed Regulatory authorizations or approvals. Shareholders and patients will welcome these authorizations and approvals to get lenz into the market. This was, after all, the primary focus of management, prior to 2020.